Join the club for FREE to access the whole archive and other member benefits.

Investing in the Longevity industry


Key points from article :

Longevity research has been evolving as a legitimate science for many years.

Edwards thinks the scale in Longevity industry will go from a 2 to an 8 in the next four to five years.

Life Biosciences now is focusing on cell reprogramming.

Longevity revolution can be valuable for Big Pharma if they will switch to being in the healthspan business.

Edwards believes 20–30 years will be added to the average lifespan with none of the ageing diseases

Mentioned in this article:

Click on resource name for more details.

Life Biosciences

Drug development company promoting longevity and finding treatments for age-related diseases

Mehmood Khan

Chief Executive Officer at Hevolution Foundation

Tristan Edwards

Co-Founder of Life Biosciences, Executive Chairman at Proto Axiom